



Interleukin-6 and intrapulmonary shunt

Francisco Perez-Vizcaino^{1,2,3}, Laura Moreno^{1,2,3} and José A. Lorente^{2,4,5}

¹Dept of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. ²CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain. ³Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain. ⁴Critical Care Service, Hospital Universitario de Getafe, Madrid, Spain. ⁵Universidad Europea, Madrid, Spain.

Francisco Perez-Vizcaino (fperez@med.ucm.es)

Check for updates	Shareable abstract (@ERSpublications) Based on animal studies and indirect clinical evidence, it may be speculated that IL-6 has a pathophysiological role in intrapulmonary shunt associated to COVID-19 https://bit.ly/3whQVqd
	Cite this article as: Perez-Vizcaino F, Moreno L, Lorente JA. Interleukin-6 and intrapulmonary shunt. <i>Eur Respir J</i> 2021; 58: 2101292 [DOI: 10.1183/13993003.01292-2021].
	This single-page version can be shared freely online.
Copyright ©The authors 2021.	To the Editor:
This version is distributed under the terms of the Creative Commons Attribution Non- Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org Received: 5 May 2021 Accepted: 6 June 2021	We read with interest the article by KOTWICA <i>et al.</i> [1] showing the utility of clinical pulse oximetry measurements to quantify shunt and ventilation–perfusion mismatch and their predictive value in severe coronavirus disease 2019 (COVID-19). The authors found that shunt correlated with markers of activated inflammatory response (<i>i.e.</i> C-reactive protein) but not those of activated coagulation (such as D-dimer). Their results reinforce the growing evidence for the role of impaired hypoxic pulmonary vasoconstriction (HPV) as a primary cause for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced hypoxaemia [2].

